In the IFN-α-treated population, patients reporting sleep disturbances had a higher risk of developing major depression.24 In our sample, there was a higher proportion of zolpidem users and anxiety disorder patients in the IFN-α-induced depression group, but neither psychiatric factor interfered with the results of recurrent depression risk (Table 4). This evidence concerns the gene IFNA1 and depressive symptom measurement.